Clinicians' self-reported efficacy in cardiovascular prevention practice in the southeastern United States.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2023-09-01 Epub Date: 2023-11-02 DOI:10.2217/fca-2023-0040

Trevor Caldarera, Cynthia Ponir, Austin Seals, Megha Penmetsa, Edward Ip, Charles A German, Salim S Virani, Animita Saha, Hayden B Bosworth, Justin B Moore, Michael D Shapiro, Yashashwi Pokharel

{"title":"Clinicians' self-reported efficacy in cardiovascular prevention practice in the southeastern United States.","authors":"Trevor Caldarera, Cynthia Ponir, Austin Seals, Megha Penmetsa, Edward Ip, Charles A German, Salim S Virani, Animita Saha, Hayden B Bosworth, Justin B Moore, Michael D Shapiro, Yashashwi Pokharel","doi":"10.2217/fca-2023-0040","DOIUrl":null,"url":null,"abstract":"Aim: We assessed self-reported efficacy in cardiovascular prevention practice among internal medicine, family medicine, endocrinology and cardiology clinicians. Patients & methods: We emailed a 21-item questionnaire to 956 physicians, nurse practitioners, physician assistants and pharmacists. Results: 264 clinicians responded (median age: 39 years, 55% women, 47.9% specialists). Most expressed high self-efficacy in lifestyle counselling, prescribing statins, metformin, and aspirin in primary prevention, but low self-efficacy in managing specialized conditions like elevated lipoprotein(a). Compared with specialists, PCPs expressed lower self-efficacy in managing advanced lipid disorders and higher self-efficacy in prescribing sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Conclusion: Self-efficacy in cardiovascular prevention varied across specialties. Future research should explore relevant provider, clinic and system level factors to optimize cardiovascular prevention.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/fca-2023-0040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: We assessed self-reported efficacy in cardiovascular prevention practice among internal medicine, family medicine, endocrinology and cardiology clinicians. Patients & methods: We emailed a 21-item questionnaire to 956 physicians, nurse practitioners, physician assistants and pharmacists. Results: 264 clinicians responded (median age: 39 years, 55% women, 47.9% specialists). Most expressed high self-efficacy in lifestyle counselling, prescribing statins, metformin, and aspirin in primary prevention, but low self-efficacy in managing specialized conditions like elevated lipoprotein(a). Compared with specialists, PCPs expressed lower self-efficacy in managing advanced lipid disorders and higher self-efficacy in prescribing sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Conclusion: Self-efficacy in cardiovascular prevention varied across specialties. Future research should explore relevant provider, clinic and system level factors to optimize cardiovascular prevention.

查看原文本刊更多论文

美国东南部临床医生自我报告的心血管预防实践疗效。

目的：我们评估了内科、家庭医学、内分泌学和心脏病学临床医生在心血管预防实践中自我报告的疗效。患者和方法：我们通过电子邮件向956名医生、执业护士、医生助理和药剂师发送了一份21项问卷。结果：264名临床医生做出了回应（中位年龄：39岁，55%为女性，47.9%为专家）。大多数人在生活方式咨询中表现出较高的自我效能感，在初级预防中使用他汀类药物、二甲双胍和阿司匹林，但在管理脂蛋白升高等特殊情况时表现出较低的自我效能。与专家相比，PCP在管理晚期脂质紊乱方面表现出较低的自我效能，在开具钠-葡萄糖协同转运蛋白-2抑制剂和胰高血糖素样肽-1受体激动剂方面表现出较高的自我效能。结论：心血管预防的自我效能因专业而异。未来的研究应探索相关的提供者、临床和系统层面的因素，以优化心血管预防。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.

文献相关原料

公司名称	产品信息	采购帮参考价格